• FDA Approves Endari for Sickle Cell Disease americanpharmaceuticalreview
    July 11, 2017
    Emmaus Life Sciences announced the U.S. Food and Drug Administration (FDA) approved Endari (L-glutamine oral powder) to reduce the severe complications of sickle cell disease (SCD) in adult and pediatric patients age 5 and older.
PharmaSources Customer Service